Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Exclusion Criteria

• •1. Pregnant women or nursing mothers
• •2. With distant metastasis
• •3. With a history of malignant tumor or complicated with other malignant tumors in addition to breast cancer, except for non-melanoma skin cancer, in situ cervical cancer or other cured malignant tumor without the basis of recurrence for at least five years
• •4. With mental illness or other conditions affecting the patient compliance
• •5. With other serious diseases or medical conditions:
• •1. Congestive heart failure or unstable angina pectoris, myocardial infarction within 6 months before the enrollment, uncontrolled hypertension and uncontrolled high-risk arrhythmia considered by the investigator
• •2. Obvious neurological or psychiatric disorders, including psychosis, epileptic dementia and other diseases may affect the understanding and sign of the informed consent for
• •3. Uncontrolled acute infection
• •6. Concurrent use of other investigational drugs; or participating in other clinical trials involving investigational drugs within 30 days before this study
• •7. With allergic constitution and any known or suspected drug allergy
• •8. Not suitable for the trial considered by the investigator